Canada - English - Health Canada

metagenics, inc. - zinc (zinc sulfate) - liquid - 15mg - zinc (zinc sulfate) 15mg - minerals

Canada - English - Health Canada

general nutrition canada inc. - zinc (zinc gluconate) - tablet - 10mg - zinc (zinc gluconate) 10mg - minerals

Canada - English - Health Canada

technilab pharma inc. - zinc oxide - cream - 15% - zinc oxide 15% - basic ointments and protectants

Canada - English - Health Canada

holista health (canada) inc. - zinc (zinc citrate) - lozenge - 5mg - zinc (zinc citrate) 5mg - minerals

Canada - English - Health Canada

laboratoire lalco inc. - zinc (zinc gluconate) - tablet - 50mg - zinc (zinc gluconate) 50mg - minerals

Canada - English - Health Canada

stanley pharmaceuticals, a division of vita health products inc. - zinc (zinc gluconate) - lozenge - 10mg - zinc (zinc gluconate) 10mg

Canada - English - Health Canada

herbalife international of america, inc. - zinc (zinc gluconate) - lozenge - 10mg - zinc (zinc gluconate) 10mg - minerals

Canada - English - Health Canada

preferred nutrition inc. - zinc (zinc citrate) - tablet - 50mg - zinc (zinc citrate) 50mg - minerals

United States - English - NLM (National Library of Medicine)

the honest company, inc. - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - zinc oxide 12%.............sunscreen helps prevent sunburn if used as directed with other sun protection measures (see directions) decreases the risk of skin cancer and early skin aging cuased by the sun

United States - English - NLM (National Library of Medicine)

piramal critical care inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [ see warnings and precautions ( 5.6) ]. risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc. parenteral nutrition with zinc should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration ( 2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions ( 5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients. in general, dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.